Protagonist Q1 2024 Earnings Report
Key Takeaways
Protagonist Therapeutics announced a transformational partnership with Takeda to develop and commercialize rusfertide, allowing reinvestment in peptide therapeutics and expansion of efforts to create a new pipeline. Enrollment is complete in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis. The company expects to nominate an oral IL-17 antagonist development candidate by the end of 2024.
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda.
Cash runway extended through Q4 2027.
Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis is now complete.
Expect to nominate a development candidate from oral IL-17 program by end of 2024.
Protagonist
Protagonist
Forward Guidance
The company expects to nominate an oral IL-17 antagonist development candidate this year from their internal discovery efforts, and anticipates results from the Phase 2b ANTHEM study in ulcerative colitis.